Insider Sell: BioMarin Pharmaceutical
1:32PM ET 5/04/2022 MT NewswiresGeorge Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
George Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
Richard A Meier, Director, on May 02, 2022, sold 3,878 shares in BioMarin Pharmaceutical (BMRN) for $318,345. Following the Form 4 filing with the SEC,...
Jean Jacques Bienaime, Director, Chief Executive Officer, on April 28, 2022, sold 25,000 shares in BioMarin Pharmaceutical (BMRN) for $2,085,550. Following...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $90 to $168, according to analysts polled by Capital IQ....
BioMarin Pharmaceutical (BMRN) on Wednesday reported Q1 earnings of $0.63 per diluted share, up from $0.09 a year ago. Analysts polled by Capital IQ...
...
Expected Earnings Release: 04/27/2022, After-hours Avg. Extended-Hours Dollar Volume: $15,979,656 Biomarin Pharmaceutical (BMRN) is due to issue its...
BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $90 to $168, according to analysts polled by Capital IQ....